Pixium Vision News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.02.24	Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings (GlobeNewswire)
17.01.24	Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024 (GlobeNewswire)
17.01.24	Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings (GlobeNewswire)
18.12.23	Decision concerning the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings scheduled for January 16, 2024 (GlobeNewswire)
04.12.23	Commercial Court hearing to examine the takeover offer scheduled for December 18, 2023 (GlobeNewswire)
20.11.23	Update on the receivership proceedings: submission of a takeover offer to the court-appointed administrators (GlobeNewswire)
14.11.23	Pixium Vision announces the 48-Month Trial Results in Severe Atrophic AMD (GlobeNewswire)
13.11.23	Pixium Vision announces the conversion of the safeguard proceedings into receivership (GlobeNewswire)
26.10.23	Pixium Vision announces its financial results for H1 2023 and provides update (GlobeNewswire)
18.10.23	Pixium Vision announces the launch of a process to find buyers (GlobeNewswire)
09.10.23	Pixium Vision announces the opening of safeguard proceedings (GlobeNewswire)
20.09.23	Pixium Vision announces the completion of the reverse stock split of its shares on the basis of 1 new share for 50 existing shares and the start of trading of the shares resulting after the completion (GlobeNewswire)
28.07.23	Pixium Vision announces the implementation of a bridge financing with Bpifrance and Sofinnova and a reverse stock split on the basis of 1 new share for 50 existing shares (GlobeNewswire)
11.07.23	Pixium Vision announces the agreement to extend the maturity date of the outstanding notes associated with the terminated ESGO financing facility (GlobeNewswire)
15.06.23	Results of the Annual General Shareholder Meeting as of June 13, 2023 (GlobeNewswire)
08.06.23	Pixium Vision announces receipt of € 1.8 million from the French Government as Research Tax Credit (GlobeNewswire)
24.05.23	Annual Meeting of Shareholders June 13, 2023 / Availability of preparatory documents (GlobeNewswire)
10.05.23	Pixium Vision convenes its Annual Meeting of Shareholders on June 13, 2023 (GlobeNewswire)
25.04.23	Pixium Vision announces the availability of its annual report for the financial year 2022 (GlobeNewswire)
21.04.23	Pixium Vision announces its consolidated financial statements for the financial year 2022 and the consolidated cash balance for March 31, 2023 (GlobeNewswire)
03.04.23	Communication following the announcement of FDA Breakthrough Device Designation for the Prima System in Dry AMD (GlobeNewswire)
31.03.23	Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD (GlobeNewswire)
17.03.23	Reduction of share capital due to losses by reduction of nominal value: number of shares unchanged (GlobeNewswire)
10.03.23	Results of Extraordinary Shareholders Meeting held on March 8, 2023 (GlobeNewswire)
28.02.23	Extraordinary Shareholder Meeting of March 8, 2023: Notice of publication of the preparatory documents (GlobeNewswire)
16.02.23	Second convening of the Extraordinary Shareholder Meeting on March 8, 2023 (GlobeNewswire)
15.02.23	Pixium Vision announces termination of convertible note financing agreement with US-based healthcare investor ESGO (GlobeNewswire)
14.02.23	Pixium Vision announces its cash position at 31 December 2022 and provides an update on its activities (GlobeNewswire)
13.02.23	Pixium Vision announces termination of convertible note financing agreement with US-based healthcare investor ESGO (GlobeNewswire)
15.11.22	Pixium Vision announces participation in investor conferences in November and December 2022 (GlobeNewswire)
11.10.22	Pixium Vision announces the publication of peer-reviewed clinical data of the Prima System in Dry AMD in the Journal of Neural Engineering (GlobeNewswire)
04.10.22	Pixium Vision announces participation in investor conferences and events in October 2022 (GlobeNewswire)
21.09.22	Pixium Vision to host open house event for investors on October 13th 2022 from 5 pm (GlobeNewswire)
19.09.22	Pixium Vision announces reaching its enrollment target in the European pivotal trial PRIMAvera and implantations planned to be completed by end 2022 (GlobeNewswire)
13.09.22	Pixium Vision announces implantation of first patient in Italy in Prima System European pivotal trial PRIMAvera (GlobeNewswire)
06.09.22	Pixium Vision announces participation in upcoming investor conferences in September 2022 (GlobeNewswire)
29.08.22	Pixium Vision announces participation in upcoming scientific conferences in September 2022 (GlobeNewswire)
11.08.22	Pixium Vision to attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022 (GlobeNewswire)
03.08.22	Pixium Vision announces regulatory approval of remote rehabilitation system for patients in clinical trials (GlobeNewswire)
26.07.22	Pixium Vision announces successful implantation of first patient in the Netherlands in Prima System European pivotal trial PRIMAvera (GlobeNewswire)
22.07.22	Pixium Vision announces its financial results for H1 2022 and provides a business update (GlobeNewswire)
14.07.22	Pixium Vision announces the implementation of a financing of a maximum nominal amount of €30 million, and the drawdown of a first tranche of €5.5 million. (GlobeNewswire)
24.06.22	Pixium Vision expands its Board of Directors with the appointment of Anja Krammer and August Moretti (GlobeNewswire)
29.04.22	Pixium Vision announces the availability of its audited financial statements for the financial year 2021 (GlobeNewswire)
28.04.22	Results of Combined General Meeting held on April 19, 2022 (GlobeNewswire)
19.04.22	Pixium Vision announces its cash position at 31 March 2022 and provides an update on its activities and financial outlook until the end of 2022 (GlobeNewswire)
04.04.22	Combined General Meeting of April 19, 2022: Availability of preparatory documents (GlobeNewswire)
29.03.22	Pixium Vision announces FDA approval of clinical trial expansion of Prima System US feasibility study to Stanford Medicine (GlobeNewswire)
24.03.22	Pixium Vision to participate in the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest on March 28 - 30 (GlobeNewswire)
14.03.22	Pixium Vision convenes a Combined General Meeting of Shareholders on April 19, 2022 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Pixium Vision SA

Aktien Top/Flop

Meistgelesene Nachrichten